{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T14:31:57Z","timestamp":1782397917239,"version":"3.54.5"},"reference-count":28,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,9,13]],"date-time":"2016-09-13T00:00:00Z","timestamp":1473724800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1016\/j.amjmed.2016.06.007","type":"journal-article","created":{"date-parts":[[2016,8,31]],"date-time":"2016-08-31T01:44:37Z","timestamp":1472607877000},"page":"S64-S72","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"special_numbering":"S","title":["Idarucizumab, a Specific Reversal Agent for Dabigatran: Mode of Action, Pharmacokinetics and Pharmacodynamics, and Safety and Efficacy in Phase 1 Subjects"],"prefix":"10.1016","volume":"129","author":[{"given":"Paul A.","family":"Reilly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"van Ryn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Grottke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Glund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Stangier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjmed.2016.06.007_bib1","unstructured":"Boehringer Ingelheim Pharmaceuticals, Inc. Pradaxa (dabigatran etexilate mesylate) prescribing information. Available at: http:\/\/bidocs.boehringer-ingelheim.com\/BIWebAccess\/ViewServlet.ser?docBase=renetnt&folderPath=\/Prescribing%20Information\/PIs\/Pradaxa\/Pradaxa.pdf. Accessed February 17,\u00a02016."},{"key":"10.1016\/j.amjmed.2016.06.007_bib2","unstructured":"Bristol-Myers Squibb. Eliquis (apixaban) prescribing information. Available at: http:\/\/packageinserts.bms.com\/pi\/pi_eliquis.pdf. Accessed February 17,\u00a02016."},{"key":"10.1016\/j.amjmed.2016.06.007_bib3","unstructured":"Daiichi Sankyo, Inc Savaysa (edoxaban) prescribing information. Available at: http:\/\/dsi.com\/prescribing-information-portlet\/getPIContent?productName=Savaysa&inline=true. Accessed February 17,\u00a02016."},{"key":"10.1016\/j.amjmed.2016.06.007_bib4","unstructured":"Janssen Pharmaceuticals, Inc. Xarelto (rivaroxaban) prescribing information. Available at: www.xareltohcp.com\/shared\/product\/xarelto\/prescribing-information.pdf. Accessed February 17,\u00a02016."},{"key":"10.1016\/j.amjmed.2016.06.007_bib5","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1111\/jth.12651","article-title":"Comparing mortality in patients with atrial fibrillation who are receiving a direct-acting oral anticoagulant or warfarin: a meta-analysis of randomized trials","volume":"12","author":"Liew","year":"2014","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.amjmed.2016.06.007_bib6","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.amjmed.2016.06.007_bib7","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.thromres.2014.07.001","article-title":"Case fatality of bleeding and recurrent venous thromboembolism during, initial therapy with direct oral anticoagulants: a systematic review","volume":"134","author":"Wu","year":"2014","journal-title":"Thromb Res"},{"key":"10.1016\/j.amjmed.2016.06.007_bib8","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1182\/blood-2012-11-468207","article-title":"A\u00a0specific antidote for dabigatran: functional and structural characterization","volume":"121","author":"Schiele","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.amjmed.2016.06.007_bib9","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1160\/TH14-11-0982","article-title":"Reversal of anticoagulants: an overview of current developments","volume":"113","author":"Greinacher","year":"2015","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.amjmed.2016.06.007_bib10","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nm.3102","article-title":"A\u00a0specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa","volume":"19","author":"Lu","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.amjmed.2016.06.007_bib11","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1056\/NEJMc1411800","article-title":"Use of PER977 to reverse the anticoagulant effect of edoxaban","volume":"371","author":"Ansell","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.amjmed.2016.06.007_bib12","unstructured":"Boehringer Ingelheim, Inc. Praxbind prescribing information. Food and Drug Administration. Available at: www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/761025lbl.pdf. Accessed February 17,\u00a02016."},{"key":"10.1016\/j.amjmed.2016.06.007_bib13","unstructured":"Boehringer Ingelheim International GmbH. Praxbind summary of product characteristics. Available at: www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/003986\/WC500197462.pdf. Accessed February 17,\u00a02016."},{"key":"10.1016\/j.amjmed.2016.06.007_bib14","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1160\/TH15-03-0192","article-title":"Design and rationale for RE-VERSE AD: a phase 3 study of idarucizumab, a specific reversal agent for dabigatran","volume":"114","author":"Pollack","year":"2015","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.amjmed.2016.06.007_bib15","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/S0140-6736(15)60732-2","article-title":"Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial","volume":"386","author":"Glund","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.amjmed.2016.06.007_bib16","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1182\/blood.V124.21.2878.2878","article-title":"Idarucizumab fully restores dabigatran-induced alterations on platelet and fibrin deposition on damaged vessels: studies in\u00a0vitro with circulating human blood","volume":"124","author":"Arellano-Rodrigo","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.amjmed.2016.06.007_bib17","doi-asserted-by":"crossref","first-page":"R27","DOI":"10.1186\/cc13717","article-title":"Prothrombin complex concentrates and a specific antidote to dabigatran are effective ex-vivo in reversing the effects of dabigatran in an anticoagulation\/liver trauma experimental model","volume":"18","author":"Grottke","year":"2014","journal-title":"Crit Care"},{"key":"10.1016\/j.amjmed.2016.06.007_bib18","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1016\/j.jacc.2015.07.051","article-title":"Idarucizumab, a specific dabigatran reversal agent, reduces blood loss in a porcine model of trauma with dabigatran anticoagulation","volume":"66","author":"Grottke","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.amjmed.2016.06.007_bib19","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1097\/ALN.0000000000000863","article-title":"Prothrombin complex concentrate is effective in treating the anticoagulant effects of dabigatran in a porcine polytrauma model","volume":"123","author":"Honickel","year":"2015","journal-title":"Anesthesiology"},{"key":"10.1016\/j.amjmed.2016.06.007_bib20","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1160\/th15-03-0266","article-title":"Therapy with activated prothrombin complex concentrate is effective in reducing dabigatran-associated blood loss in a porcine polytrauma model","volume":"115","author":"Honickel","year":"2016","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.amjmed.2016.06.007_bib21","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1160\/TH14-12-1080","article-title":"A\u00a0randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran","volume":"113","author":"Glund","year":"2015","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.amjmed.2016.06.007_bib22","article-title":"Effect of age and renal function on idarucizumab pharmacokinetics and idarucizumab-mediated reversal of dabigatran anticoagulant activity in a randomized, double-blind, crossover phase Ib study","author":"Glund","year":"2016","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.amjmed.2016.06.007_bib23","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jacc.2013.07.104","article-title":"The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy)","volume":"63","author":"Reilly","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.amjmed.2016.06.007_bib24","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/j.jacc.2016.01.043","article-title":"Restarting dabigatran etexilate 24 h after reversal with idarucizumab and redosing idarucizumab in healthy volunteers","volume":"67","author":"Glund","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"13_S","key":"10.1016\/j.amjmed.2016.06.007_bib25","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1016\/S0735-1097(16)32290-2","article-title":"Evaluation of the immunogenicity of the dabigatran reversal agent idarucizumab: pooled analysis of phase I data","volume":"67","author":"van Ryn","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjmed.2016.06.007_bib26","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.amjmed.2016.06.007_bib27","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1502000","article-title":"Idarucizumab for dabigatran reversal","volume":"373","author":"Pollack","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.amjmed.2016.06.007_bib28","unstructured":"Pollack CV, Jr, Reilly PA, Eikelboom J, et al. Idarucizumab for dabigatran reversal. http:\/\/www.nejm.org\/doi\/suppl\/10.1056\/NEJMoa1502000\/suppl_file\/nejmoa1502000_protocol.pdf. Accessed July 27, 2016."}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934316306635?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934316306635?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T09:09:06Z","timestamp":1757581746000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002934316306635"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":28,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["S0002934316306635"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2016.06.007","relation":{},"ISSN":["0002-9343"],"issn-type":[{"value":"0002-9343","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Idarucizumab, a Specific Reversal Agent for Dabigatran: Mode of Action, Pharmacokinetics and Pharmacodynamics, and Safety and Efficacy in Phase 1 Subjects","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2016.06.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}